Q-omics provides the consensus-scored FCGBP profile across patient tissues and cancer cell-line models. FCGBP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FCGBP is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, FCGBP RNA expression shows 14,940 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where FCGBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGBP survival associations across molecular data types. FCGBP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGBP RNA expression–survival associations across cancer types. High FCGBP expression shows unfavorable associations in OV, KICH and LIHC, but favorable associations in HNSC, UVM and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FCGBP RNA expression.
This table summarizes FCGBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FCGBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGBP shows lower tumor expression in THCA, COAD, KICH, HNSC and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher FCGBP RNA expression in normal versus tumor tissue (log2 FC = −3.564, t-test p < 0.001).
This table shows molecular features associated with FCGBP in patient tissues and cancer cell lines. In patient samples, FCGBP shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LIVER.
